Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK)

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. engages in the research and development of immuno-oncology therapies. The company is headquartered in Wuhan, Hubei. The company went IPO on 2025-12-23. The Company’s core products include HX009, HX301, HX044, and HX008. HX009 is a bifunctional anti-PD-1 antibody SIRP fusion protein, aiming at enhancing PD-1 function and creating a PD-1 molecule. HX301 is a multi-targeted kinase inhibitor with a unique kinase inhibition profile. HX044 is a clinical-stage drug for treatment of various types of malignancies, particularly PD-1-resistant solid tumors. HX008 is a humanized antagonist mAb against human PD-1 by using human IgG4 isotype, which can inhibit the PD-1 signal to restore the capability of the immune cells to kill cancer cells through blocking PD-1 binding to their ligands PD-L1 and PD-L2.